Mp03-16 First Safety Outcomes of Contireflex® Artificial Urinary Sphincter for Treating Male Incontinence

You have accessJournal of UrologyUrodynamics/Lower Urinary Tract Dysfunction/Female Pelvic Medicine: Male Incontinence (MP03)1 May 2024MP03-16 FIRST SAFETY OUTCOMES OF CONTIREFLEX® ARTIFICIAL URINARY SPHINCTER FOR TREATING MALE INCONTINENCE Steven K. Wilson, Eric Chung, Brian Langford, Rowland Rees, Dominic Lee, Ricardo Schlessinger, George Koufogiannis, Daniel Moon, and Koenraad Van Renterghem Steven K. WilsonSteven K. Wilson , Eric ChungEric Chung , Brian LangfordBrian Langford , Rowland ReesRowland Rees , Dominic LeeDominic Lee , Ricardo SchlessingerRicardo Schlessinger , George KoufogiannisGeorge Koufogiannis , Daniel MoonDaniel Moon , and Koenraad Van RenterghemKoenraad Van Renterghem View All Author Informationhttps://doi.org/10.1097/01.JU.0001009488.55564.85.16AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: The ContiReflex® is a new artificial urinary sphincter (AUS) implanted to address male stress incontinence. ContiReflex® is not FDA cleared; USA pre-market approval study will be conducted in 2024. The device appearance resembles the AMS 800 but has two bladders in the pressure regulating balloon. One bladder maintains constant 49-60 mm of H20 pressure and the second bladder reflexly prohibits sudden higher abdominal pressure from creating urinary accidents. Cuff sizes are graduated in 0.25 cm increments between 3.5-5 cm. METHODS: We assess the surgical outcomes and safety profile of the first 50 patients implanted between April 2022 and October 2023 from Patient Information Forms (PIF) with patient demographics, surgical details, and etiology. Mean age was 72.66 years (57–84). RESULTS: Most common reason (80%) for implantation was post-radical prostatectomy. Early in our series, 2 patients required anesthesia (4%) for pump activation. Initially the ContiReflex® pump was difficult to activate; this was corrected by use of a softer silicone and activation problems have ceased in the last 30 cases. One revision operation (2%) was required for incorrect cuff sizing. There were no reported infections or erosions. Most patients (78%) received the classic two incision method while 22% were done by the one incision scrotal technique. Kaplan-Meier analysis indicates the survival rate at 18 months was 98%. CONCLUSIONS: This study demonstrates that the early safety outcomes of the Rigicon ContiReflex® sphincter device are comparable to those of other similar devices currently available on the market. Source of Funding: N/A © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e29 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Steven K. Wilson More articles by this author Eric Chung More articles by this author Brian Langford More articles by this author Rowland Rees More articles by this author Dominic Lee More articles by this author Ricardo Schlessinger More articles by this author George Koufogiannis More articles by this author Daniel Moon More articles by this author Koenraad Van Renterghem More articles by this author Expand All Advertisement PDF downloadLoading ...